To the full analysis
Xeris Biopharma Holdings stock: growth
XERSXeris Biopharma Holdings reported $291.85M in revenue for fiscal 2025, up 43.7% on the prior year, up 70.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
86.4%
per year from 2016 to 2025, per share 13.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 70.2% | 86.4% |
| Revenue per share | 30.6% | 13.5% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $1.08M | −$13.21M | −$16.12M |
| 2017 | $1.56M | −$26.55M | −$25.36M |
| 2018 | $2.47M | −$60.08M | −$57.79M |
| 2019 | $2.72M | −$125.58M | −$80.94M |
| 2020 | $20.44M | −$91.14M | −$80.94M |
| 2021 | $49.59M | −$122.73M | −$96.62M |
| 2022 | $110.25M | −$94.66M | −$103.42M |
| 2023 | $163.91M | −$62.26M | −$49.29M |
| 2024 | $203.07M | −$54.84M | −$37.85M |
| 2025 | $291.85M | $554K | $27.93M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.